

---

## AcouSort launches its first OEM product AcouPlasma<sup>OPTICAL</sup>

AcouSort launches its first OEM product, offering a unique solution that enables integrated optical measurements of blood plasma in diagnostic and analytic instruments. AcouPlasmaOptical is developed under the company's ISO13485 quality management system and is qualified to be sold on the medical device market. AcouSort now offers evaluation kits to companies that are interested in integrating the component in their systems.

*– This is a major milestone for AcouSort. We have now successfully incorporated our core technology into an OEM component with the potential to revolutionize how blood testing is performed. This is in line with healthcare's paradigm shift towards point-of-care testing of blood samples, which will make healthcare much more efficient, saving costs, time, and lives. Our long-term business strategy is to supply OEM components for automated sample preparation to the life science industry. The launch of our first OEM product, with an initial production capacity in the hundreds of thousands units per year, is a very important step towards realizing that strategy, says AcouSort's CEO Torsten Freltoft.*

AcouSort is also releasing an application note showing how optical blood plasma measurements may be automated by using AcouPlasmaOptical. Already from January and throughout the spring, AcouSort will participate in several relevant international conferences presenting and promoting AcouPlasmaOptical to the life science instrumentation community.

About 75 percent of all blood analyses require access to the blood plasma. A large part of these tests relies on optical measurement methods. The standard procedure for generating blood plasma is to perform centrifugation requiring transport to a certified lab and manual handling of the sample, thus potentially introducing errors. AcouPlasmaOptical offers a unique solution, enabling this step to be automated and integrated into analytic and diagnostic instruments that could be placed directly at the point-of-care. With this unique solution, the blood sample is analyzed directly, and the patient and doctor get the result and can take action immediately.

### **For further information on AcouSort, please contact:**

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: [torsten.freltoft@acousort.com](mailto:torsten.freltoft@acousort.com)

---

### **About AcouSort**

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases.